H.C. Wainwright lowered the firm’s price target on Boundless Bio (BOLD) to $4 from $5 and keeps a Buy rating on the shares following the Q2 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLD: